Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 37.8259
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 899558538521.0
- FreeCF/Share 10.0576
- PFCF 99.7216
- PE 48.8811
- Debt/Assets 0.3698
- DivYield 0.006
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Published: January 05, 2026 by: Market Watch
Sentiment: Positive
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Read More
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
Read More
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Read More
In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s
Published: December 31, 2025 by: Barrons
Sentiment: Positive
Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years.
Read More
Eli Lilly's New Drug Data Sets Up a High-Stakes 2026
Published: December 26, 2025 by: MarketBeat
Sentiment: Positive
Since early August, the world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.
Read More
Focus: Lilly, Novo lock horns in India's obesity drug race
Published: December 23, 2025 by: Reuters
Sentiment: Neutral
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Graham: A.I. & Fed Top 2026 Themes, Top Picks in ANET, COHR & LLY
Published: December 19, 2025 by: Schwab Network
Sentiment: Positive
Andrew Graham says the next couple weeks will be hard to "separate the signal from the noise" in the A.I.-centric rebound due to low volume trading.
Read More
Did Eli Lilly Just Find the Holy Grail of Weight Loss?
Published: December 19, 2025 by: 24/7 Wall Street
Sentiment: Positive
Eli Lilly ( NYSE:LLY ) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
3 Momentum Stocks That Could Continue Their Strong Run in 2026
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.
Read More
Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.
Published: December 17, 2025 by: Market Watch
Sentiment: Positive
“History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but there are some caveats
Read More
Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly
Published: December 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Very few investors can match Stanley Druckenmiller.
Read More
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Published: December 16, 2025 by: CNBC
Sentiment: Positive
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Read More
LLY Leading Weight Loss Trade, Hold Economic "Trickle Down Effect"
Published: December 16, 2025 by: Schwab Network
Sentiment: Positive
Tom Hulick sees Eli Lilly (LLY) leading the GLP-1 race and evolving healthcare race, noting the company's retatrutide drug as an example. He explains how the company's developments play into a larger economic story and the "MAHA movement.
Read More
Eli Lilly or Merck: Where Should Investors Put Their Money?
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
Read More
Lilly to participate in J.P. Morgan Healthcare Conference
Published: December 16, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025.
Read More
3 Healthcare Giants Just Raised Dividends—Here's Who Pays the Most
Published: December 16, 2025 by: MarketBeat
Sentiment: Positive
Major players in healthcare are increasing their commitments to return capital to shareholders, resulting in significantly higher dividends. Recent dividend announcements from major companies in the sector highlight evolving capital return strategies.
Read More
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
Read More
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Published: December 12, 2025 by: PRNewsWire
Sentiment: Neutral
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and extended time to chemotherapy by more than a year These data were published simultaneously in Annals of Oncology and will be presented today at the 2025 San Antonio Breast Cancer Symposium INDIANAPOLIS , Dec. 12, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen …
Read More
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
Read More
Eli Lilly's Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.
Published: December 11, 2025 by: Barrons
Sentiment: Positive
The company said some patients had dropped out of the trial because they felt they were losing too much weight.
Read More
2 Pharma Stocks Pop on Strong Obesity Drug Trial Results
Published: December 11, 2025 by: Schaeffers Research
Sentiment: Positive
Positive drug trial results are boosting pharmaceutical stocks today, with Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Eli Lilly & Co. (NYSE:LLY) drawing investor attention after encouraging developments for their latest obesity drugs.
Read More
Prison Fellowship Awarded $5 Million Grant From Lilly Endowment Inc. To Broaden Its Reach in Sharing Stories of Radical Restoration
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WASHINGTON, D.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Prison Fellowship, the nation's largest Christian nonprofit serving currently and formerly incarcerated people and their families and a leading advocate for criminal justice reform, today announced that it has been awarded a $5 million grant from Lilly Endowment Inc. to help millions of people come to know and love God through seeing the transformative power of Jesus in the lives of those behind bars. The grant comes through the Endowment's National Storytelling Initiative on Christian Faith and Life 2025.
Read More
Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide
Published: December 11, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) has reported positive topline results from its Phase 3 TRIUMPH-4 trial evaluating its obesity treatment retatrutide in adults with obesity and knee osteoarthritis. The investigational drug, a once-weekly injectable targeting GLP‑1, GIP, and glucagon receptors, is designed to regulate appetite and metabolism through multiple hormone pathways.
Read More
Abivax stock pops on Eli Lilly takeover speculation
Published: December 10, 2025 by: Proactive Investors
Sentiment: Positive
Abivax SA (NASDAQ:ABVX, EPA:ABVX), a French biotechnology firm, saw its US-listed shares jump more than 11% on rumors it may be acquired by Eli Lilly and Co (NYSE:LLY). First reported by Reuters, neither Abivax nor Eli Lilly have confirmed the reports.
Read More
Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO's two-thirds market cap decline stems from a series of adverse events, some justified but many overdone, with the market ignoring positive developments. Despite recent underperformance versus Eli Lilly, NVO maintains industry-leading margins, robust cash flow, and strong growth prospects, notably with oral GLP-1 candidates.
Read More
Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
Published: December 09, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply chains.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000